摘要
目的分析阿瑞匹坦联合托烷司琼治疗化疗引起的中-重度恶心呕吐的疗效及不良反应。方法收集接受单药托烷司琼止吐治疗后轻度缓解及无效的患者,相同化疗方案下按治疗方法不同分为托烷司琼单药组(对照组,n=107)与阿瑞匹坦联合托烷司琼组(联合用药组,n=106),对比两组止吐治疗效果及不良反应。结果可评价疗效的213例患者中,对照组和联合用药组对急性恶心呕吐的有效控制率分别为13.1%与95.3%(P﹤0.01),对延迟性恶心呕吐的有效控制率分别为37.4%与96.2%(P﹤0.01)。两组方案的主要不良反应包括呃逆、便秘、头痛、头晕、口干、焦虑等,不良反应发生率比较,差异无统计学意义(P﹥0.05)。结论阿瑞匹坦联合托烷司琼方案对化疗引起的中-重度恶心呕吐有较好的疗效,不良反应可以耐受。
Objective To analyze the clinical efficacy of aprepitant combined with tropisetron in the treatment of nau-sea and vomiting induced by chemotherapy and drug-related adverse reactions （ADR）. Method Patients with partial re-sponse or nonresponsive to tropisetron antemetic monotherapy were enrolled in the study, and then were administered with tropisetron monotherapy （n=107） or aprepitant combined with tropisetron （n=106）, respectively, the antiemetic effect and adverse reactions in the two groups were analyzed. Result Among 213 evaluable patients, the control rates of acute nausea and vomiting by tropisetron or aprepitant＋tropisetron were 13.1%and 95.3%respectively （P〈0.01）, the control rates of delayed nausea and vomiting were 37.4%and 96.2%（P〈0.01）. The most common ADR of both regimens were hiccups, constipation, headache, dizziness, dry mouth, anxiety, etc., with no statistical significance observed for the inci-dence of ADR （P〉0.05）. Conclusion The aprepitant combined with tropisetron regimen is effective for moderate/severe nausea and vomiting induced by chemotherapy with tolerable toxicity profile.
出处
《癌症进展》
2017年第4期408-410,431,共4页
Oncology Progress
关键词
阿瑞匹坦
托烷司琼
化疗
中-重度恶心呕吐
治疗效果
aprepitant
tropisetron
chemotherapy
moderate/severe nausea and vomiting
clinical efficacy
